CVRx said today that it raised a $113 million funding round it plans to use to complete a pivotal clinical trial of its Barostim Neo neurostimulation device for treating heart failure. The round consists of a $93 million equity round and a $20 million debt facility, the Minneapolis-based company said. CVRx, which reported raising $46.5 million in a […]
Search Results for: cvrx
Report: CVRx CEO Yared tapped to succeed BD’s Forlenza as AdvaMed chairman Nadim Yared, the CEO of CVRx, is reportedly slated to replace Becton Dickinson (NYSE:BDX) chief executive Vincent Forlenza as chairman of AdvaMed, the medical device industry’s national lobby in Washington. It’s the 1st time the Advanced Medical Technology Assn. will have a small company’s […]
CVRx raised $46.5 million and has another $25.1 million waiting in the wings once it achieves ” a certain milestone,” the company said in a regulatory filing last week. Seventeen unnamed investors participated in the round, according to the filing, taking Minneapolis-based CVRx’s total raise since its 2001 founding to $237.1 million. CVRx, which said in the […]
CVRx said today that it won a fast-track designation from the FDA that could shave 1 or 2 years from the timeline to approval for its Barostim Neo heart failure treatment. The Barostim Neo device is a neurostimulation implant designed to treat heart failure by influencing both the sympathetic and parasympathetic nervous systems, reducing sympathetic activity […]
The principal investigator in an early feasibility study of CVRx‘s Barostim device said today that the company won FDA approval for a pivotal trial later this year, after reporting strong results from an early feasibility trial of the device.
LifeScience Alley, the Minneapolis-based trade association of medical device and life science companies, has chosen a new board chair and made other changes to its board of directors.
CVRx said its Barostim neo system was granted expanded CE Mark approval in the European Union for use with MRI procedures.
CVRx said today that it won CE Mark approval in the European Union for its Barostim Neo device to treat heart failure patients using vagus nerve stimulation.
CVRx said it added $12 million from DaVita HealthCare, Ysios Capital and others to its Series F funding round, taking the total for the round to $42 million.
The Minneapolis-based company is planning to use the money to advance clinical trials and expand its international commercial footprint, according to a press release. CVRx developed the Barostim Neo, a pacemaker-like device designed to treat hypertension.